Medical benefit pharmaceutical policies for providers
See the latest updates to our medical benefit pharmaceutical policies.
MBP 144.0 Tecentriq (atezolizumab)
Tecentriq (atezolizumab) is a humanized monoclonal antibody immune checkpoint inhibitor that binds to programmed death ligand 1 (PD-L1) to selectively prevent the interaction between the programmed cell death 1 (PD-1) and B7.1 (also known as CD80) receptors, while still allowing interaction between PD-L2 and PD-1. PD-L1 is an immune check point protein expressed on tumor cells and tumor infiltrating cells and down regulates anti-tumor T-cell function by binding to PD-1 and B7.1; blocking PD-1 and B7.1 interactions restores antitumor T-cell function.
MBP 158.0 Tepadina (thiotepa)
Tepadina (thiotepa) is an alkylating agent that produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.
MBP 217.0 Tepezza (teprotumumab-trbw)
Tepezza (teprotumumab-trbw) is an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Monoclonal Antibody that binds to insulin-like growth factor-1 receptor inhibitor and blocks its activation and signaling. Teprotumumab's mechanism of action in patients with thyroid eye disease has not been fully characterized.
New Policy 7/21/20
MBP 65.0 Torisel (temsirolimus)
Torisel (temsirolimus) is an mTOR kinase inhibitor. It is metabolized to sirolimus and suppresses the production of proteins that control progression through cell cycle and angiogenesis.
MBP 204.0 Triptodur (triptorelin)
Triptodur (triptorelin) is an agonist analog of gonadotropin releasing hormone (GnRH) and causes suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. After chronic and continuous administration, usually 2 to 4 weeks after initiation, a sustained decrease in LH and FSH secretion occurs. When used for assisted reproductive technologies (ART), prevents premature LH surge in women undergoing controlled ovarian hyperstimulation.
New Policy 11/19/19
MBP 172.0 Trisenox (arsenic trioxide)
Trisenox (arsenic trioxide) is an arsenical which induces apoptosis in APL cells via morphological changes and DNA fragmentation. It also damages or degrades the fusion protein promyelocytic leukemia (PML)-retinoic acid receptor (RAR) alpha
MBP 216.0 Trodelvy (sacituzumab govitecan-hziy)
Trodelvy (sacituzumab govitecan-hziy) is an antibody drug conjugate that consists of a humanized antitrophoblast cell-surface antigen 2 (Trop-2) monoclonal antibody coupled to the topoisomerase 1 inhibitor SN-38 via a cleavable linker (Bardia 2019). Trop-2 is overexpressed in many epithelial cancers and is associated with cancer cell growth; it has been detected in breast cancer cells (including triple-negative breast cancer cells). Sacituzumab govitecan binds to Trop-2 and is internalized; SN-38 is released in tumors both intracellularly and in the tumor microenvironment, leading to DNA damage, apoptosis, and cell death.
New Policy 7/21/20
MBP 57.0 Tysabri (natalizumab)
Tysabri (natalizumab) is a monoclonal antibody bioengineered from part of a mouse antibody to closely resemble a human antibody and binds to a protein called alpha-4-integrin. Integrins are found primarily on the surface of white blood cells which are thought to play a major role in causing the damage to the nervous system in multiple sclerosis (MS). Natalizumab blocks adhesion and subsequent migration of leukocytes into the gut by binding the α - 4 integrin thereby reducing chronic inflammation associated with Crohn’s disease.
Learn more about Geisinger Health Plan.
Log in to NaviNet to access and view prior authorization information.
Clinical guidelines offer providers consistent and appropriate guidance for diagnosis and treatment of specific conditions or diseases.
Terms and conditions
View GHP’s terms and conditions.
Questions? Contact us
If you have questions or need more information, contact Geisinger Health Plan.